HOB End Period Cash Flow from 2010 to 2024

688656 Stock   111.45  1.35  1.23%   
HOB Biotech's End Period Cash Flow is increasing over the years with slightly volatile fluctuation. End Period Cash Flow is expected to dwindle to about 138.8 M. From 2010 to 2024 HOB Biotech End Period Cash Flow quarterly data regression line had arithmetic mean of  81,771,817 and r-squared of  0.40. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
163.5 M
Current Value
138.8 M
Quarterly Volatility
116.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check HOB Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HOB Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 40.2 M, Interest Expense of 1.9 M or Selling General Administrative of 110.9 M, as well as many indicators such as . HOB financial statements analysis is a perfect complement when working with HOB Biotech Valuation or Volatility modules.
  
This module can also supplement various HOB Biotech Technical models . Check out the analysis of HOB Biotech Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in HOB Stock

HOB Biotech financial ratios help investors to determine whether HOB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HOB with respect to the benefits of owning HOB Biotech security.